Diagnosing pancreatic cancer using urine metabolites
Development of Pancreatic Cancer Diagnostic Method by Using a Reagent for Analyzing Purine Metabolite (Hypoxanthine, Xanthine) in Urine
Seoul National University Hospital · NCT06291779
This study is trying to see if testing urine for certain substances can help doctors find pancreatic cancer earlier and more easily than current methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Seoul National University Hospital (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Seongnam, Gyeonggi-do) |
| Trial ID | NCT06291779 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a diagnostic method for pancreatic cancer by analyzing purine metabolites, specifically hypoxanthine and xanthine, in urine samples. The study involves a collaboration between CubeBio and Seoul National University Bundang Hospital to compare the performance of existing diagnostic methods with the new urine analysis technique. By quantitatively assessing these metabolites in both healthy individuals and pancreatic cancer patients, the study seeks to establish a reliable and cost-effective screening tool for early detection of pancreatic cancer, which is crucial for improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients with pathologically confirmed pancreatic ductal adenocarcinoma or those with characteristic radiologic features.
Not a fit: Patients with a history of other malignancies or severe inflammatory diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could provide a safer and more accessible screening option for early diagnosis of pancreatic cancer.
How similar studies have performed: While the approach of using urine metabolites for cancer diagnosis is promising, this specific method is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
1. pancreatic cancer group Inclusion Criteria: * Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features * Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy) * Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon * Patients with informed consent Exclusion Criteria: * History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment) * Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis) * Patients with underlying diseases at high risk of general anesthesia * Other subject whom the investigator deems inappropriate 2. control group Inclusion Criteria included healthy individuals as well as patients with benign diseases. Exclusion criteria for the control group included a previous cancer diagnosis within the past five years, active inflammatory diseases, borderline malignant pancreatic tumors, or a postoperative pathological finding of malignancy.
Where this trial is running
Seongnam, Gyeonggi-do
- Ho-Seong Han — Seongnam, Gyeonggi-do, Korea, Republic of (RECRUITING)
Study contacts
- Principal investigator: Ho-Seong Han, M.D. Ph.D. — Seoul National University Bundang Hospital
- Study coordinator: MeeYoung Kang, M.D.
- Email: rime0317@gmail.com
- Phone: 82-10-5575-8881
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreas Cancer, Diagnosis, Pancreatic cancer, hypoxanthine/xanthine concentration in urine